Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 28;2(Suppl 1):i50-i61.
doi: 10.1093/noajnl/vdz049. eCollection 2020 Jul.

Genetics of human malignant peripheral nerve sheath tumors

Alexander Pemov  1 , Hua Li  2 , William Presley  2 , Margaret R Wallace  2   3 , David T Miller  4
Affiliations
Review

Genetics of human malignant peripheral nerve sheath tumors

Alexander Pemov et al. Neurooncol Adv. .

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are heterogeneous, highly aggressive tumors with no widely effective treatment other than surgery. Genomic architecture of MPNST is similar to other soft tissue sarcomas, with a relatively modest burden of single nucleotide variants and an elevated frequency of copy-number alterations. Recent advances in genomic studies identified previously unrecognized critical involvement of polycomb repressor complex 2 (PRC2) core components SUZ12 and EED in transition to malignancy. Notably, somatic changes in NF1, CDKN2A/B, and PRC2 are found in most MPNST regardless of their etiology (e.g. neurofibromatosis type 1-associated vs. sporadic vs. radiation-induced), indicating that similar molecular mechanisms impact pathogenesis in these neoplasms. The timing and specific order of genetic or epigenetic changes may, however, explain the typically poorer prognosis of NF1-associated MPNSTs. Studies that reveal genes and regulatory pathways uniquely altered in malignancies are essential to development of targeted tumor therapies. Characterization of MPNST molecular profiles may also contribute to tools for earlier detection, and prediction of prognosis or drug response. Here we review the genetic discoveries and their implications in understanding MPNST biology.

Keywords: Epigenomics; MPNST; NF1; genomics; transcriptome.

PubMed Disclaimer

References

    1. Bates JE, Peterson CR, Dhakal S, et al. . Malignant peripheral nerve sheath tumors (MPNST): a SEER analysis of incidence across the age spectrum and therapeutic interventions in the pediatric population. Pediatr Blood Cancer. 2014;61(11):1955–1960. - PubMed
    1. Gutmann DH, Ferner RE, Listernick RH, et al. . Neurofibromatosis type 1. Nat Rev Dis Primers. 2017;3:17004. - PubMed
    1. Longo JF, Weber SM, Turner-Ivey BP, et al. . Recent advances in the diagnosis and pathogenesis of neurofibromatosis type 1 (NF1)-associated peripheral nervous system neoplasms. Adv Anat Pathol. 2018;25(5):353–368. - PMC - PubMed
    1. Kehrer-Sawatzki H, Mautner VF, Cooper DN. Emerging genotype–phenotype relationships in patients with large NF1 deletions. Hum Genet. 2017;136(4):349–376. - PMC - PubMed
    1. Pemov A, Li H, Patidar R, et al. . The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. Oncogene. 2017;36(22):3168–3177. - PMC - PubMed